Innovative Biologics Inc Washington, DC - 20003

Innovative Biologics Inc is categorized under Wholesale Pharmaceutical Products in Washington, DC and active since 2004.

Innovative Biologics Inc was established in 2004, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Wholesale Pharmaceutical Products business, which does work in the B2B market, and is classified as a Wholesale Pharmaceutical Products, under code number 424210 by the NAICS.

If you are seeking more information, feel free to contact C W Gilluly at the company’s single location by writing to 415 1st St Se, Washington, District of Columbia DC 20003 or by phoning (202) 546-4367. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Innovative Biologics Inc
Contact Person: C W Gilluly
Address: 415 1st St Se, Washington, District of Columbia 20003
Phone Number: (202) 546-4367
Annual Revenue (USD): $500.000 to $999.999
Founded: 2004
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Wholesale Pharmaceutical Products
SIC Code: 5122
NAICS Code: 424210
Share This Business:

Innovative Biologics Inc was started in 2004 to provide professional Wholesale Pharmaceutical Products under the SIC code 5122 and NAICS code 424210. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.

Feel free to contact C W Gilluly for inquiries that concern Innovative Biologics Inc by calling the company number (202) 546-4367, as your correspondence is most welcome. Additionally, the physical location of the single location of Innovative Biologics Inc can be found at the coordinates 38.884592,-77.006047 as well as the street address 415 1st St Se in Washington, District of Columbia 20003.

For its online presence, you may visit Innovative Biologics Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.